Yamashita N, Ishibashi H, Hayashida K, Kudo J, Takenaka K, Itoh K, Niho Y
First Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Hepatology. 1996 Dec;24(6):1437-40. doi: 10.1053/jhep.1996.v24.pm0008938177.
The MAGE-1 gene, originally isolated from a human melanoma cell line, directs the expression of a potential tumor-rejection antigen, MZ2-E. This antigen is recognized by autologous cytotoxic T lymphocytes in association with a major histocompatibility complex class I molecule (HLA-A1), and has provided a basis for specific immunotherapy for melanoma patients. Here we show a high frequency of expression of the MAGE-1 gene in hepatocellular carcinoma (HCC). We examined the expression of the MAGE-1 gene in cell lines originated from hepatoma cells and in tumor and nontumor tissues of livers with HCC by reverse-transcription polymerase chain reaction (RT-PCR) and subsequent Southern blotting. MAGE-1 messenger RNA (mRNA) was expressed in three of four HCC cell lines (75%) and in 16 of 20 (80%) resected HCCs though none was detected in nontumor tissues. The high frequency expression of MAGE-1 gene in HCCs suggests the possibility as a target for tumor-specific immunotherapy for HCC patients.
MAGE-1基因最初是从人黑色素瘤细胞系中分离出来的，它指导一种潜在的肿瘤排斥抗原MZ2-E的表达。这种抗原与主要组织相容性复合体I类分子（HLA-A1）相关联，可被自体细胞毒性T淋巴细胞识别，为黑色素瘤患者的特异性免疫治疗提供了依据。在此我们展示了MAGE-1基因在肝细胞癌（HCC）中的高表达频率。我们通过逆转录聚合酶链反应（RT-PCR）及随后的Southern印迹法，检测了源自肝癌细胞的细胞系以及肝癌患者肝脏的肿瘤组织和非肿瘤组织中MAGE-1基因的表达情况。MAGE-1信使核糖核酸（mRNA）在四个肝癌细胞系中的三个（75%）以及20个切除的肝癌中的16个（80%）中表达，而在非肿瘤组织中均未检测到。MAGE-1基因在肝癌中的高频率表达提示其有可能成为肝癌患者肿瘤特异性免疫治疗的靶点。
